September 8, 2017 / 11:13 AM / 18 days ago

BRIEF-Karyopharm presents selinexor, KPT-9274 clinical data

Sept 8 (Reuters) - Karyopharm Therapeutics Inc

* Karyopharm announces presentation of selinexor and KPT-9274 clinical data at the European Society of Medical Oncology 2017 annual meeting

* Karyopharm Therapeutics - ‍top-line Phase 1 selinexor data in combination with chemotherapy show encouraging early efficacy in patients with ovarian, endometrial cancers​

* Karyopharm Therapeutics Inc - ‍top-line Phase 1 KPT-9274 data show a manageable safety profile and early signals of anti-tumor activity​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below